FATE实时信号 | 通过Getagraph.com最大化利润

购买 107646 min ago

@ $6.43

发出时间: 15 Feb 2024 @ 04:38

回报率: -38.57%

上一信号: Feb 15 - 02:20

上一信号: 出售

回报率: -1.30 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:45):

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide...

Stats
今日成交量	1.06M
平均成交量	2.72M
市值	449.58M
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $-0.480 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.41
ATR14	$0.0260 (0.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Redmile Group, Llc	Buy	3 636 364	Pre-Funded Warrants to Purchase Common Stock
2024-03-04	Dulac Edward J Iii	Sell	2 447	Common Stock
2024-02-01	Wolchko J Scott	Buy	500 000	Stock Option (Right to Buy)
2024-02-01	Tahl Cindy	Buy	425 000	Stock Option (Right to Buy)
2024-02-01	Dulac Edward J Iii	Buy	425 000	Stock Option (Right to Buy)

INSIDER POWER
40.61
Last 99 transactions
Buy: 17 254 718 \| Sell: 8 388 589

音量相关性

長: -0.13 (neutral)

短: 0.44 (neutral)

Signal:(45.202) Neutral

Fate Therapeutics Inc 相关性

10 最正相关
STRC	0.974
ONCS	0.971
WISA	0.97
TTCF	0.969
IMRX	0.968
LUMO	0.964
GROM	0.961
VIRX	0.957
IMCC	0.956
MEDS	0.956

10 最负相关
NWFL	-0.96
IBEX	-0.95
MNKD	-0.947
PWOD	-0.942
LRFC	-0.935
HZNP	-0.934
XOMAO	-0.931
PDD	-0.931
IMMR	-0.93
ISIG	-0.93

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Fate Therapeutics Inc 相关性 - 货币/商品

-0.41
( neutral )

-0.52
( weak negative )

0.00
( neutral )

0.51
( weak )

0.41
( neutral )

0.86
( strong )

Fate Therapeutics Inc 财务报表

Annual	2023
营收:	$63.53M
毛利润:	$45.25M (71.22 %)
EPS:	$-1.640

FY	2023
营收:	$63.53M
毛利润:	$45.25M (71.22 %)
EPS:	$-1.640

FY	2022
营收:	$96.30M
毛利润:	$82.54M (85.71 %)
EPS:	$-2.63

FY	2021
营收:	$55.85M
毛利润:	$55.85M (100.00 %)
EPS:	$-2.24

Financial Reports:

No articles found.

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

实时更新： Fate Therapeutics Inc [FATE]

Upcoming Earnings Alert